Sec Form 4 Filing - Kummeth Charles R. @ BIO-TECHNE Corp - 2023-07-21

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Kummeth Charles R. 2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [ TECH] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) 614 MCKINLEY PLACE NE 3. Date of Earliest Transaction (MM/DD/YY) 07/21/2023 (Street) MINNEAPOLIS, MN55413 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/21/2023 S( 1 ) 80,000 D $ 88.3628 ( 2 ) 1,258,766 D ( 3 ) Common Stock 400 I By Step-Son Common Stock 400 I By Step-Daughter

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Options (Right to Buy) $ 31.2625 ( 4 ) 08/09/2024 Common Stock 779,084 779,084 D Stock Options (Right to Buy) $ 44.33 ( 4 ) 08/08/2025 Common Stock 361,336 361,336 D Stock Options (Right to Buy) $ 44.33 ( 4 ) 08/08/2025 Common Stock 240,888 240,888 D Stock Options (Right to Buy) $ 47.6025 ( 4 ) 08/07/2026 Common Stock 342,900 342,900 D Restricted Stock Units ( 5 ) ( 6 ) ( 5 ) Common Stock 52,900 52,900 D Stock Options (Right to Buy) $ 47.6025 ( 7 ) 08/07/2026 Common Stock 228,600 228,600 D Restricted Stock Units ( 5 ) ( 8 ) ( 7 ) Common Stock 51,516 51,516 D Stock Options (Right to Buy) $ 66.9675 ( 8 ) 08/05/2027 Common Stock 299,768 299,768 D Stock Options (Right to Buy) $ 66.9675 ( 9 ) 08/05/2027 Common Stock 153,180 153,180 D Stock Options (Right to Buy) $ 66.9675 ( 10 ) 08/05/2027 Common Stock 66,600 66,600 D Stock Options (Right to Buy) $ 66.9675 ( 11 ) 08/05/2027 Common Stock 66,600 66,600 D Restricted Stock Units ( 5 ) ( 12 ) ( 11 ) Common Stock 32,064 32,064 D Stock Options (Right to Buy) $ 120.455 ( 12 ) 08/06/2028 Common Stock 125,260 125,260 D Stock Options (Right to Buy) $ 120.455 ( 13 ) 08/06/2028 Common Stock 83,504 83,504 D Stock Options (Right to Buy) $ 94.52 ( 14 ) 08/15/2029 Common Stock 1,200,000 1,200,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Kummeth Charles R. 614 MCKINLEY PLACE NE MINNEAPOLIS, MN55413 X Chief Executive Officer Signatures /s/ Andrew Nick, as Attorney-in-Fact pursuant to Power of Attorney previously filed. 07/25/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022. ( 2 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.95 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. ( 3 )Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024. ( 4 )Fully exercisable. ( 5 )Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. ( 6 )17,632 shares vest on each of 8/15/2023 and 8/15/2025, and 17,636 shares vest on 8/15/2024. ( 7 )Options to purchase 57,152 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 57,148 shares vest on each of 8/7/2022 and 8/7/2023. ( 8 )Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 9 )Options to purchase 38,292 shares vest on 8/5/21 and options to purchase 38,296 shares vest on each of 8/5/22, 8/5/23 and 8/5/24. ( 10 )Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021. ( 11 )Options to purchase 22,200 shares vest on each of 8/5/21, 8/5/22 and 8/5/23. ( 12 )Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). ( 13 )Options to purchase 20,876 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025. ( 14 )600,000 options vest in full or in part on 7/1/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator), and 600,000 options vest in full or in part on 7/1/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.